{"id":49332,"date":"2025-11-22T00:53:18","date_gmt":"2025-11-21T23:53:18","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/11\/22\/lymphotropic-virotherapy-induces-dc-and-high-endothelial-venule-inflammation-promoting-the-antitumor-efficacy-of-intratumor-virus-administration\/"},"modified":"2025-11-22T00:53:18","modified_gmt":"2025-11-21T23:53:18","slug":"lymphotropic-virotherapy-induces-dc-and-high-endothelial-venule-inflammation-promoting-the-antitumor-efficacy-of-intratumor-virus-administration","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/11\/22\/lymphotropic-virotherapy-induces-dc-and-high-endothelial-venule-inflammation-promoting-the-antitumor-efficacy-of-intratumor-virus-administration\/","title":{"rendered":"Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2025 Nov 21. doi: 10.1158\/2326-6066.CIR-25-0756. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Tumor-draining lymph nodes are a pivotal site for antitumor T-cell priming. However, their mechanistic roles in cancer immune surveillance and immunotherapy response remain poorly defined. Intratumor (IT) virotherapy generates antitumor T-cell immunity through multifaceted engagement of innate antiviral inflammation. Here we identify type-I interferon (IFN-I) signaling in glioma-draining cervical lymph nodes as a mediator of IT polio virotherapy. Transient IFN-I signaling after IT administration was rescued by cervical perilymphatic infusion (CPLI) virotherapy, targeting cervical lymph nodes directly. Dual-site (IT+CPLI) virotherapy induced profound inflammatory reprogramming of cervical lymph nodes, enhanced viral RNA replication and IFN-I signaling in dendritic cells and high endothelial venules, augmented antiglioma efficacy in mice, and was associated with T-cell activation in patients with recurrent glioblastoma. A Phase 2 clinical trial of IT+CPLI polio virotherapy is ongoing (NCT06177964). This study implicates the lymphatic system as a virotherapy target and demonstrates that CPLI virotherapy has the potential to complement brain tumor immunotherapy.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41270238\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20251121185318&amp;v=2.18.0.post22+67771e2\">41270238<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-25-0756\">10.1158\/2326-6066.CIR-25-0756<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2025 Nov 21. doi: 10.1158\/2326-6066.CIR-25-0756. Online ahead of print. ABSTRACT Tumor-draining lymph nodes are a pivotal site for antitumor T-cell priming. However, their mechanistic roles in cancer immune surveillance and immunotherapy response remain poorly defined. Intratumor (IT) virotherapy generates antitumor T-cell immunity through multifaceted engagement of innate antiviral inflammation. Here we identify &#8230; <a title=\"Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/11\/22\/lymphotropic-virotherapy-induces-dc-and-high-endothelial-venule-inflammation-promoting-the-antitumor-efficacy-of-intratumor-virus-administration\/\" aria-label=\"Read more about Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-49332","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/49332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=49332"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/49332\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=49332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=49332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=49332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}